Marginally failed study for Europe [Study As­sess­ment]

posted by balakotu – India, 2018-04-24 07:30  – Posting: # 18726
Views: 1,466

Hi,
I have conducted a full replicate BE study for one of the highly variable product for Europe regulatory.
Based on the reference product variability, relaxed 90% Confidence Intervals is 75.18 to 133.01 for Cmax.
Study marginally failed with 90% upper CI data of 133.18
Is there any way to justify Europe regulatory authority(ies) to accept this study data? (DCP submission)

Regards


Edit: Category changed; see also this post #1 and #4. [Helmut]

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,402 posts in 4,122 threads, 1,323 registered users;
online 13 (0 registered, 13 guests [including 5 identified bots]).
Forum time (Europe/Vienna): 14:43 CEST

No rational argument will have a rational effect on a man
who does not want to adopt a rational attitude.    Karl R. Popper

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5